Mountain Crest V furnishes investor presentation for AUM deal; no new material info

Mountain Crest Acquisition Corp. V

SPAC entered business combination agreement with AUM Biosciences on Oct 19, 2022, amended multiple times through April 19, 2023.
Exhibit 99.1 is a form investor presentation used for management meetings; no new specific financial data or guidance disclosed.
Presentation includes standard forward-looking statements and risk factors typical for pre-clinical biotech SPAC deals.
Holdco has filed an F-4 registration statement with SEC; stockholders urged to read proxy statement/prospectus when available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.